Neurotherapeutics

, Volume 5, Issue 2, pp 237–251

Therapeutic potentials of human embryonic stem cells in Parkinson’s disease

Restorative Approach Cellular Therapies for Parkinson’s Disease
  • 631 Downloads

Summary

The loss of dopaminergic neurons of the substantia nigra is the pathological hallmark characteristic of Parkinson’s disease (PD). The strategy of replacing these degenerating neurons with other cells that produce dopamine has been the main approach in the cell transplantation field for PD research. The isolation, differentiation, and long-term cultivation of human embryonic stem cells and the therapeutic research discovery made in relation to the beneficial properties of neurotrophic and neural growth factors has advanced the transplantation field beyond dopamine-producing cells. The present review addresses recent advances in human embryonic stem cell experimentation in relation to treating PD, as well as cell transplantation techniques in conjunction with alternative therapeutics.

Key Words

Neurotrophic microenvironment cytokines growth factors chemokines progenitor cells precursor cells neural stem cells transplantation central nervous system injury repair 

References

  1. 1.
    Newman MB, Freeman TB, Hart CD, Sanberg PR. Neural stem cells for cellular therapy in humans. In: Bottenstein JE, editor. Neural stem cells: development and transplantation. New York: Kluwer Academic, 2003: 379–412.Google Scholar
  2. 2.
    Ludwig CL, Weinberger DR, Bruno G, et al. Buspirone, Parkinson’s disease, and the locus ceruleus. Clin Neuropharmacol 1986; 9: 373–378.PubMedGoogle Scholar
  3. 3.
    Chan-Palay V. Depression and dementia in Parkinson’s disease: catecholamine changes in the locus ceruleus, a basis for therapy. Adv Neurol 1993;60: 438–446.PubMedGoogle Scholar
  4. 4.
    Chan-Palay V. Locus coeruleus and norepinephrine in Parkinson’s disease. Jpn J Psychiatry Neurol 1991;45: 519–521.PubMedGoogle Scholar
  5. 5.
    Mavridis M, Degryse AD, Lategan AJ, Marien MR, Colpaert FC. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson’s disease. Neuroscience 1991;41: 507–523.PubMedGoogle Scholar
  6. 6.
    Sandyk R. Hypothalamic—locus coeruleus mechanisms in the pathophysiology of “on-off” in L-dopa treated Parkinson’s disease: a hypothesis. Int J Neurosci 1989;47: 303–308.PubMedGoogle Scholar
  7. 7.
    Gesi M, Soldani P, Giorgi FS, Santinami A, Bonaccorsi I, Fomai F. The role of the locus coeruleus in the development of Parkinson’s disease. Neurosci Biobehav Rev 2000;24: 655–668.PubMedGoogle Scholar
  8. 8.
    Bertrand E, Lechowicz W, Szpak GM, Dymecki J. Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson’s disease. Folia Neuropathol 1997;35: 80–86.PubMedGoogle Scholar
  9. 9.
    Hoogendijk WJ, Pool CW, Troost D, van Zwieten E, Swaab DF. Image analyser-assisted morphometry of the locus coeruleus in Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Brain 1995;118: 131–143.PubMedGoogle Scholar
  10. 10.
    Zweig RM, Cardillo JE, Cohen M, Giere S, Hedreen JC. The locus ceruleus and dementia in Parkinson’s disease. Neurology 1993;43: 986–991.PubMedGoogle Scholar
  11. 11.
    Menendez P, Bueno C, Wang L. Human embryonic stem cells: a journey beyond cell replacement therapies. Cytotherapy 2006;8: 530–541.PubMedGoogle Scholar
  12. 12.
    Bankiewicz KS, Leff SE, Nagy D, et al. Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson’s disease. Exp Neurol 1997;144: 147–156.PubMedGoogle Scholar
  13. 13.
    Raymon HK, Thode S, Gage FH. Application of ex vivo gene therapy in the treatment of Parkinson’s disease [Erratum in: Exp Neurol 2003;25:i]. Exp Neurol 1997;144: 82–91.PubMedGoogle Scholar
  14. 14.
    Mogi M, Nagatsu T. Neurotrophins and cytokines in Parkinson’s disease. Adv Neurol 1999;80: 135–139.PubMedGoogle Scholar
  15. 15.
    Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson’s disease. Br J Pharmacol 2007;150: 963–976.PubMedGoogle Scholar
  16. 16.
    Collier TJ, Sortwell CE, Elsworth JD, et al. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson’s disease. J Comp Neurol 2002;442: 320–330.PubMedGoogle Scholar
  17. 17.
    Henderson JK, Draper JS, Baillie HS, et al. Preimplantation human embryos and embryonic stem cells show comparable expression of stage-specific embryonic antigens. Stem Cells 2002;20: 329–337.PubMedGoogle Scholar
  18. 18.
    Brederlau A, Correia AS, Anisimov SV, et al. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson’s disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 2006;24: 1433–1440.PubMedGoogle Scholar
  19. 19.
    Goldman SA, Roy NS, Beal MF, Cleren C. Large stem cell grafts could lead to erroneous interpretations of behavioral results? Nat Med 2007;13: 118–119.PubMedGoogle Scholar
  20. 20.
    Redmond DE Jr, Bjugstad KB, Teng YD, et al. Behavioral improvement in a primate Parkinson’s model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci U S A 2007;104: 12175–12180.PubMedGoogle Scholar
  21. 21.
    Redmond DE Jr, Vinuela A, Kordower JH, Isacson O. Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson’s disease. Neurobiol Dis 2008;29: 103–116.PubMedGoogle Scholar
  22. 22.
    Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 2001;344: 710–719.PubMedGoogle Scholar
  23. 23.
    Olanow CW, Brin MF. Surgical therapies for Parkinson’s disease: a physician’s perspective. Adv Neurol 2001;86: 421–433.PubMedGoogle Scholar
  24. 24.
    Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 2003;54: 403–414.PubMedGoogle Scholar
  25. 25.
    Kordower JH, Goetz CG, Freeman TB, Olanow CW. Dopaminergic transplants in patients with Parkinson’s disease: neuroanatomical correlates of clinical recovery. Exp Neurol 1997;144: 41–46.PubMedGoogle Scholar
  26. 26.
    Freed CR, Breeze RE, Schneck SA. Transplantation of fetal mesencephalic tissue in Parkinson’s disease. N Engl J Med 1995;333: 730–731.PubMedGoogle Scholar
  27. 27.
    Freeman TB, Willing A, Zigova T, Sanberg PR, Hauser RA. Neural transplantation in Parkinson’s disease. Adv Neurol 2001; 86: 435–445.PubMedGoogle Scholar
  28. 28.
    Björklund A, Dunnett SB, Brundin P, et al. Neural transplantation for the treatment of Parkinson’s disease. Lancet Neurol 2003;2: 437–445.PubMedGoogle Scholar
  29. 29.
    Kordower JH, Freeman TB, Chen EY, et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson’s disease. Mov Disord 1998;13: 383–393.PubMedGoogle Scholar
  30. 30.
    Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson’s disease. Trends Neurosci 1996; 19: 102–109.PubMedGoogle Scholar
  31. 31.
    Lajtha LG. Bone marrow: the seedbed of blood. In: Wintrobe MM, editor. Blood, pure and eloquent. New York: McGraw-Hill, 1980. p. 80–94.Google Scholar
  32. 32.
    Lajtha LG. Strategic reserves. Blood Cells 1980;6: 381–389.PubMedGoogle Scholar
  33. 33.
    Lajtha LG. Haemopoietic stem cells: concept and definitions. Blood Cells 1979;5: 447–455.PubMedGoogle Scholar
  34. 34.
    Lajtha LG. Stem cell concepts. Nouv Rev Fr Hematol 1979;21: 59–65.PubMedGoogle Scholar
  35. 35.
    Schofield R, Lajtha LG. Determination of the probability of self-renewal in haemopoietic stem cells: a puzzle. Blood Cells 1983; 9: 467–483.PubMedGoogle Scholar
  36. 36.
    Rao MS, Mattson MP. Stem cells and aging: expanding the possibilities. Mech Ageing Dev 2001;122: 713–734.PubMedGoogle Scholar
  37. 37.
    Gage FH. Mammalian neural stem cells. Science 2000;287: 1433–1438.PubMedGoogle Scholar
  38. 38.
    Shihabuddin LS, Palmer TD, Gage FH. The search for neural progenitor cells: prospects for the therapy of neurodegenerative disease. Mol Med Today 1999;5: 474–480.PubMedGoogle Scholar
  39. 39.
    Shihabuddin LS, Ray J, Gage FH. Stem cell technology for basic science and clinical applications. Arch Neurol 1999;56: 29–32.PubMedGoogle Scholar
  40. 40.
    Rao SG. Stem cells and their therapeutic potential. Indian J Exp Biol 2001;39: 1205–1206.PubMedGoogle Scholar
  41. 41.
    Seaberg RM, van der Kooy D. Stem and progenitor cells: the premature desertion of rigorous definitions. Trends Neurosci 2003;26: 125–131.PubMedGoogle Scholar
  42. 42.
    Marshak DR, Gardner RL, Gottlieb D, editors. Stem cell biology. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2001.Google Scholar
  43. 43.
    Blau HM, Brazelton TR, Weimann JM. The evolving concept of a stem cell: entity or function? Cell 2001;105: 829–841.PubMedGoogle Scholar
  44. 44.
    Rao MS. Stem cells and CNS development. Totowa, NJ: Humana Press, 2001.Google Scholar
  45. 45.
    National Research Council (U.S.). Committee on the Biological and Biomedical Applications of Stem Cell Research.; Institute of Medicine (U.S.). Board on Neuroscience and Behavioral Health. Stem cells and the future of regenerative medicine. Washington, DC: National Academy Press, 2002.Google Scholar
  46. 46.
    Gage FH. Stem cells of the central nervous system. Curr Opin Neurobiol 1998;8: 671–676.PubMedGoogle Scholar
  47. 47.
    Broxmeyer HE. Primitive hematopoietic stem and progenitor cells in human umbilical cord blood: an alternative source of transplantable cells. Cancer Treat Res 1996;84: 139–148.PubMedGoogle Scholar
  48. 48.
    Landström U, Løvtrup S. Fate maps and cell differentiation in the amphibian embryo: an experimental study. J Embryol Exp Morphol 1979;54: 113–130.PubMedGoogle Scholar
  49. 49.
    Clarke JD, Tickle C. Fate maps old and new. Nat Cell Biol 1999;1: E103-E109.PubMedGoogle Scholar
  50. 50.
    Gage PJ, Rhoades W, Prucka SK, Hjalt T. Fate maps of neural crest and mesoderm in the mammalian eye. Invest Ophthalmol Vis Sci 2005;46: 4200–4208.PubMedGoogle Scholar
  51. 51.
    Cairns J. Mutation selection and the natural history of cancer. Nature 1975;255: 197–200.PubMedGoogle Scholar
  52. 52.
    Potten CS, editor. Stem cells: their identification and characterisation. New York: Churchill Livingstone, 1983.Google Scholar
  53. 53.
    Carpenter MK, Rosler E, Rao MS. Characterization and differentiation of human embryonic stem cells. Cloning Stem Cells 2003;5: 79–88.PubMedGoogle Scholar
  54. 54.
    Newman MB, Davis CD, Borlongan CV, Emerich D, Sanberg PR. Transplantation of human umbilical cord blood cells in the repair of CNS diseases. Expert Opin Biol Ther 2004;4: 121–130.PubMedGoogle Scholar
  55. 55.
    Meyer CH, Detta A, Kudoh C. Hitchcock’s experimental series of foetal implants for Parkinson’s disease: co-grafting ventral mesencephalon and striatum. Acta Neurochir Suppl 1995;64: 1–4.PubMedGoogle Scholar
  56. 56.
    Hoffer B, Olson L. Treatment strategies for neurodegenerative diseases based on trophic factors and cell transplantation techniques. J Neural Transm Suppl 1997;49: 1–10.PubMedGoogle Scholar
  57. 57.
    Yurek DM, Fletcher-Turner A. GDNF partially protects grafted fetal dopaminergic neurons against 6-hydroxydopamine neurotoxicity. Brain Res 1999;845: 21–27.PubMedGoogle Scholar
  58. 58.
    Mendez I, Dagher A, Hong M, et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line—derived neurotrophic factor in patients with Parkinson’s disease: report of two cases and technical considerations. J Neurosurg 2000;92: 863–869.PubMedGoogle Scholar
  59. 59.
    Willing AE, Othberg AI, Saporta S, et al. Sertoli cells enhance the survival of co-transplanted dopamine neurons. Brain Res 1999; 822: 246–250.PubMedGoogle Scholar
  60. 60.
    Imitola J, Raddassi K, Park KI, et al. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1α/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci U S A 2004;101: 18117–18122.PubMedGoogle Scholar
  61. 61.
    Thored P, Arvidsson A, Cacci E, et al. Persistent production of neurons from adult brain stem cells during recovery after stroke. Stem Cells 2006;24: 739–747.PubMedGoogle Scholar
  62. 62.
    Ji L, Allen-Hoffmann BL, de Pablo JJ, Palecek SP. Generation and differentiation of human embryonic stem cell-derived keratinocyte precursors. Tissue Eng 2006;12: 665–679.PubMedGoogle Scholar
  63. 63.
    Bradley JA, Bolton EM, Pedersen RA. Stem cell medicine encounters the immune system. Nat Rev Immunol 2002;2: 859–71.PubMedGoogle Scholar
  64. 64.
    Vanikar AV, Mishra VV, Firoz A, et al. Successful generation of donor specific hematopoietic stem cell lines from co-cultured bone marrow with human embryonic stem cell line: a new methodology. Transplant Proc 2007;39: 658–661.PubMedGoogle Scholar
  65. 65.
    Behrstock S, Svendsen CN. Combining growth factors, stem cells, and gene therapy for the aging brain. Ann N Y Acad Sci 2004;1019: 5–14.PubMedGoogle Scholar
  66. 66.
    Zhao M, Momma S, Delfani K, et al. Evidence for neurogenesis in the adult mammalian substantia nigra. Proc Natl Acad Sci U S A 2003;100: 7925–7930.PubMedGoogle Scholar
  67. 67.
    Shan X, Chi L, Bishop M, et al. Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s disease-like mice. Stem Cells 2006;24: 1280–1287.PubMedGoogle Scholar
  68. 68.
    Cai J, Chen J, Liu Y, et al. Assessing self-renewal and differentiation in human embryonic stem cell lines. Stem Cells 2006;24: 516–530.PubMedGoogle Scholar
  69. 69.
    Freed CR. Will embryonic stem cells be a useful source of dopamine neurons for transplant into patients with Parkinson’s disease? Proc Natl Acad Sci U S A 2002;99: 1755–1757.PubMedGoogle Scholar
  70. 70.
    Brimble SN, Zeng X, Weiler DA, et al. Karyotypic stability, genotyping, differentiation, feeder-free maintenance, and gene expression sampling in three human embryonic stem cell lines derived prior to August 9, 2001. Stem Cells Dev 2004;13: 585–597.PubMedGoogle Scholar
  71. 71.
    Smythe GM, Grounds MD. Exposure to tissue culture conditions can adversely affect myoblast behavior in vivo in whole muscle grafts: implications for myoblast transfer therapy. Cell Transplant 2000;9: 379–393.PubMedGoogle Scholar
  72. 72.
    Smythe GM, Hodgetts SI, Grounds MD. Immunobiology and the future of myoblast transfer therapy. Mol Ther 2000;1: 304–313.PubMedGoogle Scholar
  73. 73.
    Wang JS, Shum-Tim D, Chedrawy E, Chiu RC. The coronary delivery of marrow stromal cells for myocardial regeneration: pathophysiologic and therapeutic implications. J Thorac Cardiovasc Surg 2001;122: 699–705.PubMedGoogle Scholar
  74. 74.
    Bardin N, Francès V, Lesaule G, Horschowski N, George F, Sampol J. Identification of the S-Endo 1 endothelial-associated antigen. Biochem Biophys Res Commun 1996;218: 210–216.PubMedGoogle Scholar
  75. 75.
    Morrison SJ, Uchida N, Weissman IL. The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol 1995;11: 35–71.PubMedGoogle Scholar
  76. 76.
    Ludwig TE, Bergendahl V, Levenstein ME, et al. Feeder-independent culture of human embryonic stem cells [Erratum in: Nat Methods 2006;3:867]. Nat Methods 2006;3: 637–646.PubMedGoogle Scholar
  77. 77.
    Ludwig TE, Levenstein ME, Jones JM, et al. Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol 2006; 24: 185–187.PubMedGoogle Scholar
  78. 78.
    Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts [Erratum in: Science 1998;282(5395):1827]. Science 1998;282: 1145–1147.PubMedGoogle Scholar
  79. 79.
    Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro [Erratum in: Nat Biotechnol 2000;18:559]. Nat Biotechnol 2000;18: 399–404.PubMedGoogle Scholar
  80. 80.
    Pera MF, Trounson AO. Human embryonic stem cells: prospects for development. Development 2004;131: 5515–5525.PubMedGoogle Scholar
  81. 81.
    Pera MF, Filipczyk AA, Hawes SM, Laslett AL. Isolation, characterization, and differentiation of human embryonic stem cells. Methods Enzymol 2003;365: 429–446.PubMedGoogle Scholar
  82. 82.
    Gerami-Naini B, Dovzhenko OV, Duming M, Wegner FH, Thomson JA, Golos TG. Trophoblast differentiation in embryoid bodies derived from human embryonic stem cells. Endocrinology 2004;145: 1517–1524.PubMedGoogle Scholar
  83. 83.
    Xu RH, Chen X, Li DS, et al. BMP4 initiates human embryonic stem cell differentiation to trophoblast. Nat Biotechnol 2002;20: 1261–1264.PubMedGoogle Scholar
  84. 84.
    Hay DC, Sutherland L, Clark J, Burdon T. Oct-4 knockdown induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells. Stem Cells 2004;22: 225–235.PubMedGoogle Scholar
  85. 85.
    Zaehres H, Lensch MW, Daheron L, Stewart SA, Itskovitz-Eldor J, Daley GQ. High-efficiency RNA interference in human embryonic stem cells. Stem Cells 2005;23: 299–305.PubMedGoogle Scholar
  86. 86.
    Chen HF, Kuo HC, Chien CL, et al. Derivation, characterization and differentiation of human embryonic stem cells: comparing serum-containing versus serum-free media and evidence of germ cell differentiation. Hum Reprod 2007;22: 567–577.PubMedGoogle Scholar
  87. 87.
    Li Y, Powell S, Brunette E, Lebkowski J, Mandalam R. Expansion of human embryonic stem cells in defined serum-free medium devoid of animal-derived products. Biotechnol Bioeng 2005;91: 688–698.PubMedGoogle Scholar
  88. 88.
    Stojkovic M, Lako M, Stojkovic P, et al. Derivation of human embryonic stem cells from day-8 blastocysts recovered after three-step in vitro culture. Stem Cells 2004;22: 790–797.PubMedGoogle Scholar
  89. 89.
    Kannagi R, Cochran NA, Ishigami F, et al. Stage-specific embryonic antigens (SSEA-3 and -4) are epitopes of a unique globoseries ganglioside isolated from human teratocarcinoma cells. EMBO J 1983;2: 2355–2361.PubMedGoogle Scholar
  90. 90.
    Fenderson BA, De Miguel MP, Pyle AD, Donovan PJ. Staining embryonic stem cells using monoclonal antibodies to stage-specific embryonic antigens. Methods Mol Biol 2006;325: 207–224.PubMedGoogle Scholar
  91. 91.
    Ohmori K, Takada A, Yoneda T, et al. Differentiation-dependent expression of sialyl stage-specific embryonic antigen-1 and I-antigens on human lymphoid cells and its implications for carbohydrate-mediated adhesion to vascular endothelium. Blood 1993; 81: 101–111.PubMedGoogle Scholar
  92. 92.
    Yazawa T, Ogata T, Kamma H, Shibagaki T, Iijima T, Horiguchi H. Pulmonary blastoma with a topographic transition from blastic to more differentiated areas: an immunohistochemical assessment of its embryonic nature using stage-specific embryonic antigens. Virchows Arch A Pathol Anat Histopathol 1991;419: 513–518.PubMedGoogle Scholar
  93. 93.
    Draper JS, Pigott C, Thomson JA, Andrews PW. Surface antigens of human embryonic stem cells: changes upon differentiation in culture. J Anat 2002;200: 249–258.PubMedGoogle Scholar
  94. 94.
    Zhao M, Ren C, Yang H, et al. Transcriptional profiling of human embryonic stem cells and embryoid bodies identifies HESRG, a novel stem cell gene. Biochem Biophys Res Commun 2007;362: 916–922.PubMedGoogle Scholar
  95. 95.
    Rosler ES, Fisk GJ, Ares X, et al. Long-term culture of human embryonic stem cells in feeder-free conditions. Dev Dyn 2004; 229: 259–274.PubMedGoogle Scholar
  96. 96.
    Pruszak J, Sonntag KC, Aung MH, Sanchez-Pemaute R, Isacson O. Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations. Stem Cells 2007;25: 2257–2268.PubMedGoogle Scholar
  97. 97.
    Fukuda H, Takahashi J, Watanabe K, et al. Fluorescence-activated cell sorting-based purification of embryonic stem cell-derived neural precursors averts tumor formation after transplantation. Stem Cells 2006;24: 763–771.PubMedGoogle Scholar
  98. 98.
    Marzesco AM, Janich P, Wilsch-Brauninger M, et al. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. J Cell Sci 2005;118: 2849–2858.PubMedGoogle Scholar
  99. 99.
    Fox N, Damjanov I, Martinez-Hernandez A, Knowles BB, Solter D. Immunohistochemical localization of the early embryonic antigen (SSEA-1) in postimplantation mouse embryos and fetal and adult tissues. Dev Biol 1981;83: 391–398.PubMedGoogle Scholar
  100. 100.
    Cardoso AA, Li ML, Batard P, et al. Human umbilical cord blood CD34+ cell purification with high yield of early progenitors. J Hematother 1993;2: 275–279.PubMedGoogle Scholar
  101. 101.
    Cardoso AA, Li ML, Batard P, et al. Release from quiescence of CD34+ CD38 human umbilical cord blood cells reveals their potentiality to engraft adults. Proc Natl Acad Sci U S A 1993; 90: 8707–8711.PubMedGoogle Scholar
  102. 102.
    Healy L, May G, Gale K, et al. The stem cell antigen CD34 functions as a regulator of hemopoietic cell adhesion. Proc Natl Acad Sci U S A 1995;92: 12240–12244.PubMedGoogle Scholar
  103. 103.
    Lu L, Xiao M, Shen RN, Grigsby S, Broxmeyer HE. Enrichment, characterization, and responsiveness of single primitive CD34 human umbilical cord blood hematopoietic progenitors with high proliferative and replating potential. Blood 1993;81: 41–48.PubMedGoogle Scholar
  104. 104.
    Broxmeyer HE, Cooper S, Hague N, et al. Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice. Ann Hematol 1995;71: 235–246.PubMedGoogle Scholar
  105. 105.
    Broxmeyer HE. Questions to be answered regarding umbilical cord blood hematopoietic stem and progenitor cells and their use in-transplantation. Transfusion 1995;35: 694–702.PubMedGoogle Scholar
  106. 106.
    Broxmeyer HE. Cord blood as an alternative source for stem and progenitor cell transplantation. Curr Opin Pediatr 1995;7: 47–55.PubMedGoogle Scholar
  107. 107.
    Traycoff CM, Abboud MR, Laver J, Clapp DW, Hoffman R, Srour EF. Ex vivo expansion of CD34+ cells from purified adult human bone marrow and umbilical cord blood hematopoietic progenitor cells. Prog Clin Biol Res 1994;389: 385–391.PubMedGoogle Scholar
  108. 108.
    Traycoff CM, Abboud MR, Laver J, Clapp DW, Srour EF. Rapid exit from G0/G1 phases of cell cycle in response to stem cell factor confers on umbilical cord blood CD34+ cells an enhanced ex vivo expansion potential. Exp Hematol 1994;22: 1264–1272.PubMedGoogle Scholar
  109. 109.
    Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006;444: 761–765.PubMedGoogle Scholar
  110. 110.
    Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997;90: 5013–5021.PubMedGoogle Scholar
  111. 111.
    Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90: 5002–5112.PubMedGoogle Scholar
  112. 112.
    Pötgens AJ, Bolte M, Huppertz B, Kaufmann P, Frank HG. Human trophoblast contains an intracellular protein reactive with an antibody against CD133: a novel marker for trophoblast. Placenta 2001;22: 639–645.PubMedGoogle Scholar
  113. 113.
    Uchida N, Buck DW, He D, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 2000;97: 14720–14725.PubMedGoogle Scholar
  114. 114.
    Amit M, Shariki C, Margulets V, Itskovitz-Eldor J. Feeder layer- and serum-free culture of human embryonic stem cells. Biol Reprod 2004;70: 837–845.PubMedGoogle Scholar
  115. 115.
    Amit M, Winkler ME, Menke S, et al. No evidence for infection of human embryonic stem cells by feeder cell-derived murine leukemia viruses. Stem Cells 2005;23: 761–771.PubMedGoogle Scholar
  116. 116.
    Eiges R, Schuldiner M, Drukker M, Yanuka O, Itskovitz-Eldor J, Benvenisty N. Establishment of human embryonic stem cell-transfected clones carrying a marker for undifferentiated cells. Curr Biol 2001;11: 514–518.PubMedGoogle Scholar
  117. 117.
    Xu C, Inokuma MS, Denham J, et al. Feeder-free growth of undifferentiated human embryonic stem cells. Nat Biotechnol 2001;19: 971–974.PubMedGoogle Scholar
  118. 118.
    Poltavtseva RA, Marey MV, Aleksandrova MA, Revishchin AV, Korochkin LI, Sukhikh GT. Evaluation of progenitor cell cultures from human embryos for neurotransplantation. Brain Res Dev Brain Res 2002;134: 149–154.PubMedGoogle Scholar
  119. 119.
    Shih CC, Weng Y, Mamelak A, LeBon T, Hu MC, Forman SJ. Identification of a candidate human neurohematopoietic stem-cell population. Blood 2001;98: 2412–2422.PubMedGoogle Scholar
  120. 120.
    Hwang WS, Roh SI, Lee BC, et al. Patient-specific embryonic stem cells derived from human SCNT blastocysts [Erratum in: Science 2005;310:1769] [Retraction in: Kennedy D. Science 2006;311:335]. Science 2005;308: 1777–1783.PubMedGoogle Scholar
  121. 121.
    Reubinoff BE, Itsykson P, Turetsky T, et al. Neural progenitors from human embryonic stem cells. Nat Biotechnol 2001;19: 1134–1140.PubMedGoogle Scholar
  122. 122.
    Pleasure SJ, Page C, Lee VM. Pure, postmitotic, polarized human neurons derived from NTera 2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons. J Neurosci 1992;12: 1802–1815.PubMedGoogle Scholar
  123. 123.
    Zhang SC, Wemig M, Duncan ID, Brüstle O, Thomson JA. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 2001;19: 1129–1133.PubMedGoogle Scholar
  124. 124.
    Zhou JM, Chu JX, Chen XJ. An improved protocol that induces human embryonic stem cells to differentiate into neural cells in vitro. Cell Biol Int 2008;32: 80–85.PubMedGoogle Scholar
  125. 125.
    Tropepe V, Hitoshi S, Sirard C, Mak TW, Rossant J, van der Kooy D. Direct neural fate specification from embryonic stem cells: a primitive mammalian neural stem cell stage acquired through a default mechanism. Neuron 2001;30: 65–78.PubMedGoogle Scholar
  126. 126.
    Gritti A, Frölichsthal-Schoeller P, Galli R, et al. Epidermal and fibroblast growth factors behave as mitogenic regulators for a single multipotent stem cell-like population from the subventricular region of the adult mouse forebrain. J Neurosci 1999; 19: 3287–3297.PubMedGoogle Scholar
  127. 127.
    Eaton MJ, Whittemore SR. Automne BDNF secretion enhances the survival and serotonergic differentiation of raphe neuronal precursor cells grafted into the adult rat CNS. Exp Neurol 1996; 140: 105–114.PubMedGoogle Scholar
  128. 128.
    Joannides AJ, Fiore-Hériché C, Battersby AA, et al. A scaleable and defined system for generating neural stem cells from human embryonic stem cells. Stem Cells 2007;25: 731–737.PubMedGoogle Scholar
  129. 129.
    Lu J, Hou R, Booth CJ, Yang SH, Snyder M. Defined culture conditions of human embryonic stem cells. Proc Natl Acad Sci U S A 2006;103: 5688–5693.PubMedGoogle Scholar
  130. 130.
    Carpenter MK, Inokuma MS, Denham J, et al. Enrichment of neurons and neural precursors from human embryonic stem cells. Exp Neurol 2001;172: 383–397.PubMedGoogle Scholar
  131. 131.
    Kondo T, Raff M. Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. Science 2000;289: 1754–1757.PubMedGoogle Scholar
  132. 132.
    Ogawa M. Changing phenotypes of hematopoietic stem cells. Exp Hematol 2002;30: 3–6.PubMedGoogle Scholar
  133. 133.
    Snyder EY, Macklis JD. Multipotent neural progenitor or stem-like cells may be uniquely suited for therapy for some neurodegenerative conditions. Clin Neurosci 1995;3: 310–316.PubMedGoogle Scholar
  134. 134.
    Mueller FJ, Serobyan N, Schraufstatter IU, et al. Adhesive interactions between human neural stem cells and inflamed human vascular endothelium are mediated by integrins. Stem Cells 2006; 24: 2367–2372.PubMedGoogle Scholar
  135. 135.
    Takeuchi H, Natsume A, Wakabayashi T, et al. Intravenously transplanted human neural stem cells migrate to the injured spinal cord in adult mice in an SDF-1- and HGF-dependent manner. Neurosci Lett 2007;426: 69–74.PubMedGoogle Scholar
  136. 136.
    Nagatsu T, Sawada M. Cellular and molecular mechanisms of Parkinson’s disease: neurotoxins, causative genes, and inflammatory cytokines. Cell Mol Neurobiol 2006;26: 781–802.PubMedGoogle Scholar
  137. 137.
    Nagatsu T, Mogi M, Ichinose H, Togari A. Cytokines in Parkinson’s disease. J Neural Transm Suppl 2000;(58):143–151.Google Scholar
  138. 138.
    Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines and neurotrophins in Parkinson’s disease. J Neural Transm Suppl 2000;(60);277–290.Google Scholar
  139. 139.
    Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson’s disease. J Neural Transm Suppl 2006;(70);373–381.Google Scholar
  140. 140.
    Imamura K, Hishikawa N, Sawada M, et al. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol 2003;106: 518–526.PubMedGoogle Scholar
  141. 141.
    Drukker M, Katz G, Urbach A, et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Roc Natl Acad Sci U S A 2002;99: 9864–9869.Google Scholar
  142. 142.
    Grinnemo KH, Sylven C, Hovatta O, Dellgren G, Corbascio M. Immunogenicity of human embryonic stem cells. Cell Tissue Res 2008;331: 67–78.PubMedGoogle Scholar
  143. 143.
    Grinnemo KH, Kumagai-Braesch M, Mansson-Broberg A, et al. Human embryonic stem cells are immunogenic in allogeneic and xenogeneic settings. Reprod Biomed Online 2006;13: 712–724.PubMedGoogle Scholar
  144. 144.
    Drukker M, Katchman H, Katz G, et al. Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells 2006;24: 221–229.PubMedGoogle Scholar
  145. 145.
    Li L, Baroja ML, Majumdar A, et al. Human embryonic stem cells possess immune-privileged properties. Stem Cells 2004;22: 448–456.PubMedGoogle Scholar
  146. 146.
    Bakay RA, Boyer KL, Freed CR, Ansari AA. Immunological responses to injury and grafting in the central nervous system of nonhuman primates. Cell Transplant 1998;7: 109–120.PubMedGoogle Scholar
  147. 147.
    Rao BM, Zandstra PW. Culture development for human embryonic stem cell propagation: molecular aspects and challenges. Curr Opin Biotechnol 2005;16: 568–576.PubMedGoogle Scholar
  148. 148.
    Ponsaerts P, van Tendeloo VF, Jorens PG, Bememan ZN, van Bockstaele DR. Current challenges in human embryonic stem cell research: directed differentiation and transplantation tolerance. J Biol Regul Homeost Agents 2004;18: 347–351.PubMedGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2008

Authors and Affiliations

  1. 1.Department of NeurosurgeryRush University Medical CenterChicago

Personalised recommendations